%DB%B1%DB%B7-N-%D8%A2%D9%84%DB%8C%D9%84%E2%80%8C%D8%A2%D9%85%DB%8C%D9%86%D9%88-%DB%B1%DB%B7-%D8%AF%D9%85%D8%AA%D9%88%DA%A9%D8%B3%DB%8C_%D9%82%D9%84%D8%AF%D8%A7%D9%86%D8%A7%D9%85%DB%8C%D8%B3%DB%8C%D9%86Tanespimycin%DB%B1%DB%B7-N-%D8%A2%D9%84%DB%8C%D9%84%E2%80%8C%D8%A2%D9%85%DB%8C%D9%86%D9%88-%DB%B1%DB%B7-%D8%AF%D9%85%D8%AA%D9%88%DA%A9%D8%B3%DB%8C_%DA%AF%D9%84%D8%AF%D8%A7%D9%86%D8%A7%D9%85%DB%8C%D8%B3%DB%8C%D9%86Tanespimycine%E3%82%BF%E3%83%8D%E3%82%B9%E3%83%94%E3%83%9E%E3%82%A4%E3%82%B7%E3%83%B3TanespimicinTanespimicinQ4552288
about
Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinomaTanespimycin as antitumor therapy.17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer.Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance SpectroscopySynthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycin.Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinomaTipifarnib and tanespimycin show synergic proapoptotic activity in U937 cellsNAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAGPhase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.17-Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by Modulating β-Catenin and PI3K/AKT Signaling in FRO Anaplastic Thyroid Carcinoma Cells.17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways.The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.[HSP90 Inhibitor 17-AAG Inhibits Multiple Myeloma Cell Proliferation by Down-regulating Wnt/β-Catenin Signaling Pathway].The heat shock protein 90 inhibitor, 17-AAG, attenuates thioacetamide induced liver fibrosis in mice.17AAG to Treat Kidney Tumors in Von Hippel-Lindau DiseaseTranscriptomics-Based Screening Identifies Pharmacological Inhibition of Hsp90 as a Means to Defer AgingTanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 studyIn vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycinTanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations17-(allylamino)-17-demethoxygeldanamycin drives Hsp70 expression but fails to improve morphological or functional recovery in injured skeletal muscle
P921
Q28476794-45079EBF-1E8A-44C3-A490-EFFF17DE2F9EQ34026384-617738ED-805E-4E1F-94E7-CCB3F2D3888FQ34158824-ADE1DA38-970E-4DC7-8BD1-4037B6F7FB0CQ34179082-42D91941-5900-4DE2-8812-D4B1A0B9A63BQ34278997-CAC010D9-1882-40F1-BEBF-DA3A3BD7A292Q35375097-4AC9C916-824C-48CF-A9C3-FDF703CC0536Q35528633-C0F19A9C-D72C-4319-990C-6324EC976509Q35566217-E5B5005B-0FAD-4462-8537-C848B8107EE6Q35691439-291BB933-4420-4123-94A7-D2978A9295A0Q35754391-36CAFB5A-0B18-421A-9898-35F2E80E1EF1Q35979667-5B221CF6-3C07-4D97-988E-0C47B40A0D4BQ36999363-6C80E2F2-60B8-475E-B0ED-EC127965E254Q37827173-3A0FE474-8975-4019-868C-5DA8E04DC243Q38794615-68EDEFD8-FB43-43DE-8E71-E221E88DB9FDQ38832257-65302086-B29E-47BA-B623-0CA24B222C5CQ38915333-7E16CA8F-537A-4A94-8848-C33467E92441Q38968385-FEECCECB-FFF9-4678-9FCC-F245FC0C2959Q39045651-3A5D1EEA-3963-4C43-98F4-3E54D7164C28Q43410223-C8F46457-9BF9-4164-85B2-6A2C83F3AB1EQ45387477-F05D04BE-CFBF-4E59-883D-F7CA50C6BFD7Q51549127-2026FE12-38D4-4DFC-891F-E6E070C72E0CQ52883234-0FDB6A8B-10FB-4BDB-9D29-8C229BE8A8AAQ53770829-3E47055F-5718-4663-9688-032FD03D83DCQ62110228-57A68F1B-18CC-493B-8663-7BF5E99F06B7Q64062648-4FC7E60E-E912-4B73-B6FB-7999BD6BBB03Q84013087-805EB79B-2B5F-44E9-9C3D-0667A64C8577Q84145872-329454C9-C79A-483B-BA23-7BBE2B99B541Q84587884-41AD748B-4848-4944-A9F4-562BA1095958Q85908740-FC9CC389-B57C-4E93-9C41-8E5621F87957
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Tanespimicin
@sh
Tanespimicin
@sr
Tanespimycine
@fr
tanespimycin
@en
۱۷-N-آلیلآمینو-۱۷-دمتوکسی قلدانامیسین
@azb
۱۷-ان-آلیل آمینو-۱۷-دمتوکسی گلدانامیسین
@fa
タネスピマイシン
@ja
type
label
Tanespimicin
@sh
Tanespimicin
@sr
Tanespimycine
@fr
tanespimycin
@en
۱۷-N-آلیلآمینو-۱۷-دمتوکسی قلدانامیسین
@azb
۱۷-ان-آلیل آمینو-۱۷-دمتوکسی گلدانامیسین
@fa
タネスピマイシン
@ja
altLabel
17-AAG
@en
17-N-allylamino-17-demethoxygeldanamycin
@en
17-allylamino-17-demethoxygeldanamycin
@en
17AAG
@en
prefLabel
Tanespimicin
@sh
Tanespimicin
@sr
Tanespimycine
@fr
tanespimycin
@en
۱۷-N-آلیلآمینو-۱۷-دمتوکسی قلدانامیسین
@azb
۱۷-ان-آلیل آمینو-۱۷-دمتوکسی گلدانامیسین
@fa
タネスピマイシン
@ja
P592
P6366
P661
P662
P683
P2017
C[C@H]1C[C@@H]([C@@H]([C@H](/C ...... )NCC=C)\C)OC)OC(=O)N)\C)C)O)OC
P2067
585.305015
P231
75747-14-7
P233
CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC
P234
1S/C31H43N3O8/c1-8-12-33-26-21 ...... t17-,19+,24+,25+,27-,29+/m1/s1
P235
AYUNIORJHRXIBJ-HTLBVUBBSA-N
P274
C₃₁H₄₃N₃O₈
P2840
P3117
DTXSID5046352
P592
CHEMBL126955
P6366
2779671599
P652
4GY0AVT3L4